Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases.

× No keyword cloud information.

20 in total

1. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Authors: Joel M Kremer; Bradley J Bloom; Ferdinand C Breedveld; John H Coombs; Mark P Fletcher; David Gruben; Sriram Krishnaswami; Rubén Burgos-Vargas; Bethanie Wilkinson; Cristiano A F Zerbini; Samuel H Zwillich
Journal: Arthritis Rheum Date: 2009-07

Review 2. The emerging safety profile of JAK inhibitors in rheumatic disease.

Authors: Kevin L Winthrop
Journal: Nat Rev Rheumatol Date: 2017-03-02 Impact factor: 20.543

3. From clinical observations to molecular mechanisms and back to patients: the successful circuit of the CANTOS study.

Authors: Giuseppe Lembo
Journal: Cardiovasc Res Date: 2018-01-01 Impact factor: 10.787

Review 4. Psoriasis.

Authors: Jacqueline E Greb; Ari M Goldminz; James T Elder; Mark G Lebwohl; Dafna D Gladman; Jashin J Wu; Nehal N Mehta; Andrew Y Finlay; Alice B Gottlieb
Journal: Nat Rev Dis Primers Date: 2016-11-24 Impact factor: 52.329

5. Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

Authors: Joel M Kremer; Mark C Genovese; Edward Keystone; Peter C Taylor; Steven H Zuckerman; Giacomo Ruotolo; Douglas E Schlichting; Victoria L Crotzer; Eric Nantz; Scott D Beattie; William L Macias
Journal: Arthritis Rheumatol Date: 2017-05 Impact factor: 10.995

6. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.

Authors: Iain B McInnes; Ho-Youn Kim; Sang-Heon Lee; David Mandel; Yeong-Wook Song; Carol A Connell; Zhen Luo; M Julia Brosnan; Andrea Zuckerman; Samuel H Zwillich; John D Bradley
Journal: Ann Rheum Dis Date: 2013-03-12 Impact factor: 19.103

7. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.

Authors: Jashin J Wu; Bruce E Strober; Peter R Hansen; Ole Ahlehoff; Alexander Egeberg; Abrar A Qureshi; Debbie Robertson; Hernan Valdez; Huaming Tan; Robert Wolk
Journal: J Am Acad Dermatol Date: 2016-08-04 Impact factor: 11.527

8. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.

Authors: Nehal N Mehta; Daniel B Shin; Aditya A Joshi; Amit K Dey; April W Armstrong; Kristina Callis Duffin; Zelma Chiesa Fuxench; Charlotte L Harrington; Rebecca A Hubbard; Robert E Kalb; Alan Menter; Daniel J Rader; Muredach P Reilly; Eric L Simpson; Junko Takeshita; Drew A Torigian; Thomas J Werner; Andrea B Troxel; Stephen K Tyring; Suzette Baez Vanderbeek; Abby S Van Voorhees; Martin P Playford; Mark A Ahlman; Abass Alavi; Joel M Gelfand
Journal: Circ Cardiovasc Imaging Date: 2018-06 Impact factor: 7.792

Review 9. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.

Authors: Daniella M Schwartz; Michael Bonelli; Massimo Gadina; John J O'Shea
Journal: Nat Rev Rheumatol Date: 2015-12-03 Impact factor: 20.543

10. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors:
Journal: Lancet Date: 2014-12-18 Impact factor: 79.321

1 in total

Review 1. Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors: Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal: Cardiovasc Res Date: 2019-04-15 Impact factor: 10.787

1 in total